Follow-up Schedule for Patients With Sentinel Node–negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial
Conclusions:
A reduced-intensity, American Joint Committee on Cancer (AJCC) stage-adjusted follow-up schedule for sentinel node–negative melanoma patients is a safe strategy, and patient self-examination is effective for recurrence detection with no evidence of diagnostic delay. Patients’ acceptance is very high.
Source: Annals of Surgery - Category: Surgery Tags: Randomized Controlled Trials Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Melanoma | Netherlands Health | Skin Cancer | Study | Surgery | UK Health